重庆太极实业（集团）股份有限公司 章 程 二 0 二三年八月 1 重庆太极实业（集团）股份有限公司 章 程 目 录 第二节 董事会 2 第一章 总则 第二章 经营宗旨和范围 第三章 股份 第一节 股份发行 第二节 股份增减和回购 第三节 股份转让 第四章 党委会 第五章 股东和股东大会 第一节 股东 第二节 股东大会的一般规定 第三节 股东大会的召集 第四节 股东大会的提案与通知 第五节 股东大会的召开 第六节 股东大会的表决和决议 第六章 董事会 第一节 董事 3 第七章 总经理及其他高级管理人员 第八章 监事会 第一节 监事 第二节 监事会 第九章 财务会计制度、利润分配和审计 第一节 财务会计制度 第二节 内部审计 第三节 会计师事务所的聘任 第十章 通知与公告 第一节 通知 第二节 公告 第十一章 合并、分立、增资、减资、解散和清算 第一节 合并、分立、增资和减资 第二节 解散和清算 第十二章 修改章程 第十三章 附则 第一章 总 则 第一条 为了建立现代企业，维护公司、股东和债权人的合法权益，规范公 司的组织和行为，实现国有资产的保值增值，根据《中华人民共和国公司法》（以 下简称《公司法》）、《中华 ...

证券代码：600129 证券简称：太极集团 公告编号：2023-41 重庆太极实业（集团）股份有限公司 关于使用部分闲置募集资金暂时用于补充 流动资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示： 为提高募集资金使用效率，重庆太极实业（集团）股份有限公司 （以下简称：公司或太极集团）拟使用不超过 25,000 万元的闲置募 集资金补充流动资金，使用期限为自董事会审议通过之日起不超过 12 个月，到期及时归还到募集资金专用账户。 2023 年 8 月 23 日，公司第十届董事会第十五次会议、第十届监 事会第十二次会议审议通过了《关于使用部分闲置募集资金暂时用于 补充流动资金的议案》，现将相关事宜公告如下： 一、募集资金基本情况 三、前次使用部分闲置募集资金暂时用于补充流动资金到期归还 的情况 2022 年 10 月 26 日，公司第十届董事会第十次会议《关于使用 部分闲置募集资金暂时用于补充流动资金的议案》，同意公司使用不 超过 41,000 万元闲置募集资金暂时用于补充流动资金，使用期限为 自董事会审 ...

重庆太极实业（集团）股份有限公司 关于对国药集团财务有限公司的风险持续评估报告 通过查验国药集团财务有限公司（以下简称"财务公司"）《金 融许可证》、《企业法人营业执照》等证件资料，并审阅了财务公司 截至2023年半年度的财务报告以及风险指标等必要信息，对财务公司 的经营资质、业务和风险状况进行了评估，具体情况报告如下： 一、财务公司基本情况 财务公司成立于2012年2月，是经中国银行保险监督管理委员会 批准成立的非银行金融机构。 企业名称：国药集团财务有限公司 注册地址：北京市海淀区知春路20号 法定代表人：杨珊华 金融许可证机构编码：L0145H211000001 统一社会信用代码：9111000071783212X7 注册资本：人民币 220,000 万元 股东情况：中国医药集团有限公司出资 116,105 万元，中国生物 技术股份有限公司出资 69,895 万元，中国中药有限公司出资 12,000 万元，上海现代制药股份有限公司出资 12,000 万元，国药控股股份 有限公司出资 10,000 万元。 经营范围：（一）对成员单位办理财务和融资顾问、信用鉴证及 相关的咨询、代理业务；（二）协助成员单位实 ...

证券代码：600129 证券简称：太极集团 公告编号：2023-42 拟聘任的会计师事务所名称：天健会计师事务所（特殊普通合伙）， 不涉及会计师事务所的变更。 一、拟聘任的会计师事务所的基本情况 | （一）机构信息 | | --- | | 事务所名称 | 天健会计师事务所（特殊普通合伙） | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 成立日期 | 2011 7 18 | 年 | 月 | 日 | 组织形式 | | | 特殊普通合伙 | | | 注册地址 | 浙江省杭州市西湖区灵隐街道西溪路 | | | | | 128 | 号 | | | | 首席合伙人 | 胡少先 上年末合伙人数量 | | | | | | | 225 人 | | | 上年末执业人 | 注册会计师 | | | | | | | 2,064 | 人 | | 员数量 | 签署过证券服务业务审计报告的注册会计师 | | | | | | | 780 | 人 | | 2022 年（经审 | 业务收入总额 38.63 | | | | | | 亿 ...

证券代码：600129 证券简称：太极集团 公告编号：2023-37 特此公告。 重庆太极实业（集团）股份有限公司 2023 年 8 月 18 日 2022 年 10 月 26 日，重庆太极实业（集团）股份有限公司（以 下简称：公司）第十届董事会第十次会议审议通过了《关于使用部分 闲置募集资金暂时用于补充流动资金的议案》，同意公司使用不超过 41,000 万元闲置募集资金暂时用于补充流动资金，使用期限为自董 事会审议通过之日起不超过 12 个月。 2023 年 1 月 9 日，公司将上述用于补充流动资金的 16,000 万元 归还至募集资金专项账户。 具体内容详见公司刊登于《中国证券报》《上海证券报》《证券 时报》《证券日报》及上海证券交易所网站（www.sse.com.cn）的公 告（公告编号：2022-51 2022-53 2023-01） 2023 年 8 月 17 日，公司归还用于暂时补充流动资金的闲置募集 资金 25,000 万元至公司募集资金专用账户，本次归还的募集资金使 用期限未超过 12 个月。截止本公告披露日，公司用于暂时补充流动 资金的闲置募集资金 41,000 万元已全部归还。公司已将归 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 4,427,245,377.14, representing a 25.27% increase compared to CNY 3,534,245,541.53 in the same period last year[4] - Net profit attributable to shareholders was CNY 234,964,030.36, a significant increase of 991.16% from CNY 21,533,423.14 in the previous year[4] - Basic and diluted earnings per share reached CNY 0.42, up 950.00% from CNY 0.04 in the same period last year[4] - The weighted average return on equity increased by 6.61 percentage points to 7.40% compared to 0.79% in the previous year[4] - Total operating revenue for Q1 2023 reached RMB 4,427,245,377.14, an increase of 25.3% compared to RMB 3,534,245,541.53 in Q1 2022[14] - Total operating costs for Q1 2023 were RMB 4,128,707,044.10, up from RMB 3,435,516,881.19 in Q1 2022, reflecting a growth of 20.2%[14] - Net profit for Q1 2023 reached ¥236,597,822.43, a significant increase from ¥19,362,960.82 in Q1 2022, representing a growth of approximately 1,122%[15] - Revenue from sales of goods and services amounted to ¥3,589,221,222.00, up from ¥2,970,296,954.17 in the same quarter last year, indicating a year-over-year increase of about 21%[17] - Total comprehensive income for Q1 2023 was ¥236,579,781.70, compared to ¥19,355,029.97 in Q1 2022, showing an increase of approximately 1,223%[16] - Operating profit for the quarter was ¥283,030,582.49, a significant rise from ¥23,339,076.77 in the previous year, representing an increase of about 1,115%[15] Cash Flow and Assets - Cash flow from operating activities generated a net amount of CNY 238,520,917.50, a 227.59% increase from CNY 72,810,990.11 in the previous year[4] - Current assets totaled RMB 7,971,061,940.39 as of March 31, 2023, down from RMB 8,339,052,767.30 at the end of 2022, a decrease of 4.4%[11] - Cash and cash equivalents decreased to RMB 1,758,767,672.48 from RMB 2,374,432,028.57, a decline of 26.0%[11] - Accounts receivable increased to RMB 2,637,162,023.74, up 31.8% from RMB 2,001,104,912.10 in the previous year[11] - Total assets at the end of the reporting period were CNY 14,639,006,510.61, a decrease of 1.73% from CNY 14,896,326,064.64 at the end of the previous year[4] - Total liabilities decreased to RMB 11,476,764,124.54 from RMB 11,969,326,021.98, a reduction of 4.1%[13] - Non-current assets increased to RMB 6,667,944,570.22 from RMB 6,557,273,297.34, reflecting a growth of 1.7%[12] - The company reported a decrease in investment income, with a loss of ¥890,359.92 compared to a gain of ¥2,340,601.22 in Q1 2022[15] - The net cash flow from investing activities was -162,163,428.82, compared to -114,616,895.69 in the previous year, indicating a significant increase in cash outflow[18] - The total cash and cash equivalents at the end of the period amounted to 1,354,013,486.49, an increase from 809,347,247.66 year-over-year[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 19,702, with the largest shareholder holding 27.62% of the shares[8] - Shareholder equity attributable to shareholders increased by 7.64% to CNY 3,290,527,503.99 from CNY 3,056,913,540.43 at the end of the previous year[4] Expenses and Investments - Research and development expenses increased to ¥38,026,695.20, compared to ¥19,324,301.49 in Q1 2022, reflecting a growth of approximately 97%[15] - Tax expenses for the quarter were ¥47,735,484.37, compared to ¥5,516,338.30 in Q1 2022, indicating an increase of approximately 767%[15] - The company reported cash outflows for the acquisition of fixed assets and intangible assets totaling 183,126,713.50, compared to 145,099,458.79 in the previous year, marking an increase of approximately 26.2%[18] Future Plans - The company plans to focus on market expansion and new product development in the upcoming quarters[10]

Financial Performance - The company's net profit attributable to shareholders for 2022 was CNY 349,702,842.36, a significant recovery from a net loss of CNY 523,174,260.71 in 2021[3]. - Total operating revenue for 2022 reached CNY 14,050,659,364.39, representing a year-on-year increase of 15.65% compared to CNY 12,149,432,719.04 in 2021[15]. - The net cash flow from operating activities for 2022 was CNY 1,800,768,932.71, an increase of 222.25% from CNY 558,812,795.72 in 2021[15]. - The company's total assets as of the end of 2022 were CNY 14,707,197,661.95, up 11.67% from CNY 13,170,023,352.56 at the end of 2021[15]. - The net assets attributable to shareholders at the end of 2022 were CNY 3,063,772,315.86, reflecting a 12.35% increase from CNY 2,727,075,186.70 at the end of 2021[15]. - The company reported a net profit excluding non-recurring gains and losses of CNY 366,629,474.69 for 2022, compared to a loss of CNY 697,094,865.85 in 2021[15]. - Basic and diluted earnings per share were 0.63 yuan, compared to a loss of 0.94 yuan per share in 2021[16]. - The weighted average return on equity increased to 12.08%, up 29.62 percentage points from -17.54% in 2021[16]. - The company achieved a revenue of 14.051 billion yuan in the reporting period, a 15.65% increase from 12.149 billion yuan in the same period last year[38]. Operational Highlights - The company will not distribute profits for 2022 due to significant operational funding needs following its turnaround[3]. - The company has maintained a standard unqualified audit report from Tianjian Accounting Firm for the fiscal year[2]. - The company achieved a 22.5% year-on-year increase in pharmaceutical industrial output value, reaching a historical high[29]. - The company launched a digital traceability platform for traditional Chinese medicine to enhance quality control throughout the supply chain[28]. - The company established a commercial management framework "1+2+3" to enhance operational efficiency and resource integration[26]. - The company expanded its traditional Chinese medicine planting bases to 150,000 acres, adding 24,000 acres during the reporting period[27]. - The company has implemented a centralized procurement model to reduce costs while ensuring quality, with strict supplier qualification and quality analysis systems[34]. Research and Development - The total R&D expenditure amounted to CNY 161,055,946.44, which is 1.15% of total revenue, with capitalized R&D accounting for 34.32% of the total[50]. - The company has over 80 ongoing research projects, with nearly 20 new projects initiated during the reporting period[70]. - The company is focusing on the development of innovative drugs and traditional Chinese medicine formulations to address various medical conditions[70]. - The company has completed the clinical trial for the innovative traditional Chinese medicine Danqi Tongmai tablets for cardiovascular diseases and is advancing several other key projects[30]. - The company is actively promoting the integration of production, learning, and research with top research institutions to build a collaborative innovation network[30]. Market Strategy - The company plans to continue focusing on high-quality development and operational efficiency improvements in the upcoming fiscal year[23]. - The company aims for a revenue growth of over 20% year-on-year in 2023, with a target of achieving 30% growth in the pharmaceutical sector[98]. - The company is expanding its market presence in key regions, targeting nine major markets including Sichuan, Chongqing, Beijing, and Guangdong[98]. - The company is committed to improving the competitiveness of its traditional Chinese medicine products, particularly in the OTC market[99]. - The company is leveraging the aging population and rising living standards to drive demand for pharmaceutical products[96]. Corporate Governance - The board of directors consists of 15 members, with a majority being external directors, ensuring independent oversight and governance[105]. - The company emphasizes investor relations management, ensuring timely and fair information disclosure to all shareholders[106]. - The company has maintained a consistent board structure with terms for directors and supervisors set to end in May 2024[110]. - The company has not reported any significant changes in its major shareholders or related party transactions that could affect its independence[108]. - The company is focused on maintaining its operational independence from its controlling shareholders and has not identified any major competitive threats from related entities[108]. Environmental Responsibility - The company has invested a total of 21.994 million yuan in social responsibility projects, benefiting 100,000 people[165]. - The company has implemented carbon reduction measures, achieving a reduction of 5,551 tons of CO2 equivalent emissions[162]. - The company has established a total of 1 national-level green factory and 3 provincial-level green factories[160]. - The company has constructed a new wastewater treatment plant with a capacity of 5,000 tons per day at the Fuling Pharmaceutical Factory[161]. - The company has established emergency response plans for environmental incidents, with specific registration numbers for each subsidiary[156]. Future Outlook - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 1.32 billion[113]. - New product launches are expected to contribute an additional 200 million in revenue, with a focus on innovative healthcare solutions[113]. - The company is exploring potential acquisitions to strengthen its market position, with a budget of 100 million allocated for strategic acquisitions[113]. - The company plans to increase production capacity by 30% at its digital oral formulation workshop in Taiji Pharmaceutical City[101]. - The company is committed to strengthening its supply chain and increasing negotiation power for bulk purchasing to improve net profit margins[100].

证券代码：600129 证券简称：太极集团 公司编号：2023-25 重庆太极实业（集团）股份有限公司 关于召开公司 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带责任。 重要内容提示: 重庆太极实业（集团）股份有限公司（以下简称：公司）已于2023 年3月31日发布公司2022年度报告，为便于广大投资者更全面深入地 了解公司2022年度经营成果、财务状况，公司计划于2023年4月12日 （星期三）下午14:00-15:00举行2022年度业绩说明会，就投资者关 心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对2022年度 的经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在 信息披露允许的范围内就投资者普遍关注的问题进行回答。 ●会议召开时间：2023年4月12日（星期三）下午14:00-15:00 ●会议召开地点：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） ●会议召开方式：上证路演中心网络互动 ● ...